Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Triple Negative Breast Neoplasms 11Breast Neoplasms 10Carcinoma, Transitional Cell 9Small Cell Lung Carcinoma 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Neoplasm Metastasis 6Melanoma 6Colorectal Neoplasms 6Lung Neoplasms 5Recurrence 4Neoplasms 4Urinary Bladder Neoplasms 3Lymphoma, B-Cell 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Merkel Cell 2Brain Neoplasms 2Advanced Solid Tumor 2Urologic Neoplasms 1Urologic Diseases 1

Interventions

enzalutamide 4abiraterone 2Docetaxel 2tasquinimod 1sabizabulin 1olaparib 1ipatasertib 1darolutamide 1atezolizumab 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms, Castration-Resistant × atezolizumab × Clear all
NCT04404140 2023-10-17

A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Hoffmann-La Roche

Phase 1 Terminated
6 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡